Key result
Doxorubicin-induced cardiotoxicity is primarily driven by oxidative stress, mitochondrial damage, and calcium overload, and may be mitigated by medications and phytochemicals with antioxidant properties.
Why the study?
Doxorubicin is a highly cardiotoxic anticancer medication that can result in cardiomyopathy, prompting a review of its mechanisms and updated management strategies.
Design
Review
Authors
Loading...
Antioxidants merit trial evaluation for doxorubicin cardiotoxicity; evidence remains hypothesis-generating and should not yet change practice.
Understanding the molecular mechanisms of doxorubicin-induced cardiotoxicity, particularly oxidative stress and mitochondrial damage, highlights potential therapeutic targets for cardioprotection in cancer patients.
Hamaamin et al. (2022) conducted a review in Doxorubicin-induced cardiotoxicity. Cardioprotective agents (medications and phytochemicals) was evaluated. Doxorubicin-induced cardiotoxicity is primarily driven by oxidative stress, mitochondrial damage, and calcium overload, and may be mitigated by medications and phytochemicals with antioxidant properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: